The MHRA has been reviewing reports of a very rare blood clotting problem affecting a small number of people who have received the Oxford/AstraZene
The MHRA has been reviewing reports of a very rare blood clotting problem affecting a small number of people who have received the Oxford/AstraZeneca vaccine.
People under the age of 30 without other health conditions are currently advised that it is preferable to receive an alternative vaccine instead of the AstraZeneca vaccine.
At a briefing on Wednesday, Dr June Raine, chief executive of the MHRA, said the benefits of the AstraZeneca vaccine outweighs the risks for the “vast majority” of people after cases of blood clots were detected in an “extremely small” number of people.
Following Wednesday’s announcement, Prime Minister Boris Johnson said: “We will follow today’s updated advice, which should allow people of all ages to continue to have full confidence in vaccines, helping us save lives and cautiously return towards normality.”